NIHR Oxford Biomedical Research Centre

Enabling translational research through partnership

MENUMENU
  • About
    • About the NIHR Oxford Biomedical Research Centre
    • A Guide to What We Do
    • Activities during COVID-19
    • Strategic Partnership Board
    • Steering Committee
    • Promoting Equality, Diversity and Inclusion in Research
    • Current Vacancies
    • Contact Us
    • Stay in Touch
  • Research
        • OUR 20 RESEARCH THEMES

        • Antimicrobial Resistance and Modernising Microbiology
        • Cardiovascular
        • Clinical Informatics and Big Data
        • Diabetes and Metabolism
        • Gastroenterology and Mucosal Immunity
        • Genomic Medicine
        • Haematology and Stem Cells
        • Imaging
        • Molecular Diagnostics
        • Multi-Modal Cancer Therapies
        • Multi-Morbidity and Long-Term Conditions
        • Musculoskeletal
        • Neurological Conditions
        • Obesity, Diet and Lifestyle
        • Partnerships for Health, Wealth and Innovation
        • Respiratory
        • Stroke and Vascular Dementia
        • Surgical Innovation and Evaluation
        • Technology and Digital Health
        • Vaccines for Emerging and Endemic Diseases
        • Oxford Biomedical Research Centre activities during COVID-19
  • Patient & Public Involvement
    • Getting involved with research
    • Researcher Guidance
    • Post an opportunity for patient and public involvement
  • Training Hub
    • Training Hub Overview
    • Clinical Academic Pathway
    • Internships
    • Preparatory Research Fellowships
    • Senior Research Fellowships
    • Research Training Bursaries
    • Doctoral Awards
    • Post-Doctoral Awards
    • Other funding
    • Leadership Training
    • Useful Links
    • Training and Education Resources
    • Upcoming Training Events & Courses
  • Industry
    • Collaborate with Oxford BRC
    • What Can We Do For Your Organisation?
    • Who Do We Work With?
    • IP and Licensing
    • Contacts for Industry
  • Videos
  • News
  • Events

News

You are here: Home > Cardiovascular > More people could benefit from blood pressure-lowering medication, study finds

More people could benefit from blood pressure-lowering medication, study finds

30 April 2021 · Listed under Cardiovascular, Multimorbidity and Long-Term Conditions, Stroke and Vascular Dementia

Blood pressure-lowering medication can prevent serious cardiovascular conditions such as strokes, heart failure and heart attacks, even in adults with normal blood pressure, according to a new research by University of Oxford researchers

Image: Steve Buissinne from Pixabay 

In a paper published in the Lancet, the researchers found the beneficial effects of treatment were similar, regardless of the starting blood pressure level, in people who had previously had a heart attack or stroke and in those who had never had heart disease. 

The findings have immediate and important implications for global clinical guidelines that typically limit blood pressure-lowering treatment to individuals with high blood pressure (usually above 140/90 mmHg).

The study, the most detailed of its kind, included 345,000 people from 48 randomised clinical trials. It was led by Prof Kazem Rahimi, Professor of Cardiovascular Medicine and Population Health, who is supported by the NIHR Oxford Biomedical Research Centre and who leads the Deep Medicine programme at the Nuffield Department of Women’s and Reproductive Health. 

He said: “Our findings are of great importance to the debate concerning blood pressure treatment. This new and best available evidence tells us that decisions to prescribe blood pressure medication should not be based simply on a prior diagnosis of cardiovascular disease or an individual’s blood pressure level.

“Instead, medication should be viewed as an effective tool for preventing cardiovascular disease in people at increased risk of developing heart disease or stroke. Clinical guidelines should be changed to reflect these findings.” 

Prof Kazem Rahimi

He cautioned: “We’re not saying that everyone must begin treatment. The decision will depend on an individual’s risk factors for developing cardiovascular disease, the potential for side effects and patient choice.” 

Heart disease and stroke, linked to high blood pressure, are the leading cause of death across most of the western world. It is widely accepted that blood pressure medication protects people who have had a prior heart attack or stroke from having a second, but there has been debate over the use of these drugs in people with normal or mildly elevated blood pressure.

So far, studies examining whether blood pressure-lowering medication is equally beneficial in people with and without a history of cardiovascular disease, and at lower blood pressure levels than currently considered for treatment have reported conflicting findings. This has led to contradictory treatment recommendations around the world.

Over an average four-year follow-up, 42,324 participants had at least one major cardiovascular event (heart attack, stroke, heart failure, or death from cardiovascular disease). For every 5 mmHg reduction in systolic blood pressure, the risk of developing major cardiovascular disease fell by around 10%. The beneficial effects of the treatment did not differ based on a history of having had cardiovascular disease or the level of blood pressure at study entry.

← Seven in ten patients hospitalised with COVID-19 not fully recovered five months after discharge
Foods linked to greater risk of cardiovascular disease and death in middle-age identified →

News

  • Study highlights ongoing COVID-19 risk in some cancer patients despite vaccination 24 May 2022
  • BRC study outlines researchers training needs and barriers 20 May 2022
  • Three new Blood and Transplant Research Units created in Oxford 18 May 2022
See full news archive

News Categories

Month Archives

Subscribe to the Oxford BRC Newsletter

Keep informed about the work of the Oxford BRC by subscribing to our Mailchimp e-newsletter. It is produced several times a year and delivers news and information about upcoming events straight to your inbox.

Subscribe Now

Oxford BRC on Social Media

  • Facebook
  • LinkedIn
  • Twitter
  • YouTube

Feedback

We’d love to hear your feedback. Please contact us at obrcenquiries@ouh.nhs.uk

  • Sitemap
  • Data Control and Privacy
  • Accessibility
  • Our Partners
  • Disclaimer
  • Contact

Copyright © 2022 NIHR Oxford Biomedical Research Centre